"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.
GCTB generally occurs in a"...
Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism.
Dyrenium (triamterene) may be used alone or with other diuretics, either for its added diuretic effect or its potassium- sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism.
Usage in Pregnancy. The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia.
Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate.
DOSAGE AND ADMINISTRATION
Dosage should be titrated to the needs of the individual patient. When used alone, the usual starting dose is 100 mg twice daily after meals. When combined with another diuretic or antihypertensive agent, the total daily dosage of each agent should usually be lowered initially and then adjusted to the patient s needs. The total daily dosage should not exceed 300 mg. Please refer to PRECAUTIONS- General.
Capsules: 50 mg in bottles of 100, and 100 mg in bottles of 100.
Store at 25°C (77°F); excursions permitted to 15° - 30°C (59° - 86°F)[See USP Controlled Room Temperature]. Dispense in a tight, light resistant container.
50 mg 100s: NDC 65197-002-01
100 mg 100s: NDC 65197-003-01
DATE OF ISSUANCE OCTOBER 2005. Manufactured for: WellSpring Pharmaceutical Corporation, Bradenton, FL 34202-4101. USA. By: WellSpring Pharmaceutical Canada Corp. Oakville, Ontario L6H 1M5 Canada. FDA Rev date: 2/28/2002.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 5/28/2008
Additional Dyrenium Information
Dyrenium - User Reviews
Dyrenium User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.